ID
38074
Descripción
Two-Part Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Oral Dosesof the Enteric-Coated Free Base Formulation of Darapladib (SB-480848) ina Dose Rising Fashion and to Evaluate the Safety, Tolerability and Pharmacokinetics of Darapladib when Co-administered with Ketoconazole in Healthy Adult Subjects. There are 4 parts to this study: Screening, Part A, Part B, and Follow-Up. Part A contains 2 Sessions per day for day 1-10, Part B contains 1 Session per day for day 1-14. Each itemgroup contains information when it should be filled out. The itemgroups of the non-serious and serious adverse event forms contain additional information on the definition of a serious/non-serious adverse event.
Palabras clave
Versiones (1)
- 15/9/19 15/9/19 -
Titular de derechos de autor
GlaxoSmithKline
Subido en
15 de septiembre de 2019
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 3.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Darapladib Evaluation Case Report Form GSK LPL107988
Vital Signs
Similar models
Vital Signs
C0439564 (UMLS CUI [1,2])
C0040223 (UMLS CUI [1,2])
C0439659 (UMLS CUI [1,3])
C0040223 (UMLS CUI [1,2])
C0444930 (UMLS CUI [1,3])
C0038846 (UMLS CUI [1,2])
C0039155 (UMLS CUI [1,3])
C0038846 (UMLS CUI [1,2])
C0012000 (UMLS CUI [1,3])